Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 2
1979 2
1980 1
1981 1
1985 5
1986 1
1987 4
1988 2
1989 3
1990 3
1991 1
1992 9
1993 11
1994 10
1995 4
1996 10
1997 6
1998 17
1999 15
2000 22
2001 23
2002 19
2003 16
2004 21
2005 19
2006 38
2007 26
2008 49
2009 28
2010 36
2011 43
2012 28
2013 19
2014 23
2015 35
2016 25
2017 25
2018 34
2019 40
2020 34
2021 24
2022 10
2023 11
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

667 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Atypical hyperplasia of breast"
Page 1
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, Fava M, Briata IM, Giordano L, Digennaro M, Cortesi L, Falcini F, Serra P, Avino F, Millo F, Cagossi K, Gallerani E, De Simone A, Cariello A, Aprile G, Renne M, Bonanni B, DeCensi A. Lazzeroni M, et al. J Clin Oncol. 2023 Jun 10;41(17):3116-3121. doi: 10.1200/JCO.22.02900. Epub 2023 Mar 14. J Clin Oncol. 2023. PMID: 36917758 Clinical Trial.
Here, we present the 10-year results. METHODS: We randomly assigned 500 women with breast IEN (atypical ductal hyperplasia, lobular carcinoma in situ [LCIS], or hormone-sensitive or unknown DCIS) to low-dose tamoxifen or placebo after surgery with or without …
Here, we present the 10-year results. METHODS: We randomly assigned 500 women with breast IEN (atypical ductal hyperplasia …
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Fisher B, et al. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88. doi: 10.1093/jnci/90.18.1371. J Natl Cancer Inst. 1998. PMID: 9747868 Clinical Trial.
METHODS: Women (N=13388) at increased risk for breast cancer because they 1) were 60 years of age or older, 2) were 35-59 years of age with a 5-year predicted risk for breast cancer of at least 1.66%, or 3) had a history of lobular carcinoma in situ were rand …
METHODS: Women (N=13388) at increased risk for breast cancer because they 1) were 60 years of age or older, 2) were 35-59 years of ag …
European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO.
Rubio IT, Wyld L, Marotti L, Athanasiou A, Regitnig P, Catanuto G, Schoones JW, Zambon M, Camps J, Santini D, Dietz J, Sardanelli F, Varga Z, Smidt M, Sharma N, Shaaban AM, Gilbert F. Rubio IT, et al. Eur J Surg Oncol. 2024 Jan;50(1):107292. doi: 10.1016/j.ejso.2023.107292. Epub 2023 Nov 27. Eur J Surg Oncol. 2024. PMID: 38061151 Free article.
INTRODUCTION: Breast lesions of uncertain malignant potential (B3) include atypical ductal and lobular hyperplasias, lobular carcinoma in situ, flat epithelial atypia, papillary lesions, radial scars and fibroepithelial lesions as well as other rare miscellan …
INTRODUCTION: Breast lesions of uncertain malignant potential (B3) include atypical ductal and lobular hyperplasias, lo …
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Taverniti C, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Branchi D, Campora S, Petrera M, Buttiron Webber T, Boni L, Bonanni B. DeCensi A, et al. J Clin Oncol. 2019 Jul 1;37(19):1629-1637. doi: 10.1200/JCO.18.01779. Epub 2019 Apr 11. J Clin Oncol. 2019. PMID: 30973790 Free PMC article. Clinical Trial.
Biomarker trials showed that 5 mg/d is not inferior to 20 mg/d in decreasing breast cancer proliferation. We hypothesized that a lower dose given for a shorter period could be as effective in preventing recurrence from breast intraepithelial neoplasia but have a low …
Biomarker trials showed that 5 mg/d is not inferior to 20 mg/d in decreasing breast cancer proliferation. We hypothesized that a lowe …
Active Surveillance for Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ.
Miceli R, Mercado CL, Hernandez O, Chhor C. Miceli R, et al. J Breast Imaging. 2023 Jul 28;5(4):396-415. doi: 10.1093/jbi/wbad026. J Breast Imaging. 2023. PMID: 38416903 Review.
Atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) are relatively common breast lesions on the same spectrum of disease. Atypical ductal hyperblasia is a nonmalignant, high-risk lesion, and DCIS is a noninvasive malignancy. ...
Atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) are relatively common breast lesions on the same …
Reassessing risk models for atypical hyperplasia: age may not matter.
Mazzola E, Coopey SB, Griffin M, Polubriaginof F, Buckley JM, Parmigiani G, Garber JE, Smith BL, Gadd MA, Specht MC, Guidi A, Hughes KS. Mazzola E, et al. Breast Cancer Res Treat. 2017 Sep;165(2):285-291. doi: 10.1007/s10549-017-4320-7. Epub 2017 Jun 6. Breast Cancer Res Treat. 2017. PMID: 28589368 Free PMC article. Review.
PURPOSE: The aim of this study was to investigate the influence of age at diagnosis of atypical hyperplasia ("atypia", ductal [ADH], lobular [ALH], or severe ADH) on the risk of developing subsequent invasive breast cancer or ductal carcinoma in situ (DCIS). …
PURPOSE: The aim of this study was to investigate the influence of age at diagnosis of atypical hyperplasia ("atypia", ductal …
Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?
Coopey SB, Kartal K, Li C, Yala A, Barzilay R, Faulkner HR, King TA, Acevedo F, Garber JE, Guidi AJ, Hughes KS. Coopey SB, et al. Breast Cancer Res Treat. 2019 May;175(1):1-4. doi: 10.1007/s10549-018-05117-4. Epub 2019 Jan 21. Breast Cancer Res Treat. 2019. PMID: 30666539 Review.
PURPOSE: Atypical ductal hyperplasia (ADH) significantly increases the risk of breast cancer in women. However, little is known about the implications of ADH in men. METHODS: Review of 932 males with breast pathology was performed to identify cases of …
PURPOSE: Atypical ductal hyperplasia (ADH) significantly increases the risk of breast cancer in women. However, little …
An update on the management of breast atypical ductal hyperplasia.
Schiaffino S, Cozzi A, Sardanelli F. Schiaffino S, et al. Br J Radiol. 2020 Jun;93(1110):20200117. doi: 10.1259/bjr.20200117. Epub 2020 Apr 1. Br J Radiol. 2020. PMID: 32207989 Free PMC article.
Among lesions with uncertain malignant potential found at percutaneous breast biopsy, atypical ductal hyperplasia (ADH) carries both the highest risk of underestimation and the closest and most pathologist-dependent differential diagnosis with ductal carcinom …
Among lesions with uncertain malignant potential found at percutaneous breast biopsy, atypical ductal hyperplasia (ADH) …
B3 lesions of the breast and cancer risk. A single-centre experience.
Marino G, Accardo G, Thodas A, Botte M, Di Nardo G, Calice G, Patitucci G, Di Cerbo A, La Torre G. Marino G, et al. Ann Ital Chir. 2023;94:226-230. Ann Ital Chir. 2023. PMID: 37530037
METHODS: Between January 2018 and December 2021, 83 patients undergoing ultrasound guided tru-cut needle biopsy or VABB with a B3 diagnosis and surgical excision following multidisciplinary discussion were retrospectively reviewed in our Breast Unit. RESULTS: Out of a tota …
METHODS: Between January 2018 and December 2021, 83 patients undergoing ultrasound guided tru-cut needle biopsy or VABB with a B3 diagnosis …
Breast Hyperplasias, Risk Signature, and Breast Cancer.
Poola I, Yue Q, Gillespie JW, Sullivan PS, Aguilar-Jakthong J, Rao J, Shaaban AM, Sauter ER, Ricci AJ. Poola I, et al. Cancer Prev Res (Phila). 2019 Jul;12(7):471-480. doi: 10.1158/1940-6207.CAPR-19-0051. Epub 2019 Jun 25. Cancer Prev Res (Phila). 2019. PMID: 31239263
We address the dilemma faced by oncologists in administering preventative measures to "at risk" patients diagnosed with atypical and nonatypical hyperplasias due to lack of any molecular means of risk stratification and identifying high-risk subjects. ...We assayed …
We address the dilemma faced by oncologists in administering preventative measures to "at risk" patients diagnosed with atypical and …
667 results